MX345331B - Métodos para diagnosticar enfermedad degenerativa de las articulaciones. - Google Patents

Métodos para diagnosticar enfermedad degenerativa de las articulaciones.

Info

Publication number
MX345331B
MX345331B MX2013012991A MX2013012991A MX345331B MX 345331 B MX345331 B MX 345331B MX 2013012991 A MX2013012991 A MX 2013012991A MX 2013012991 A MX2013012991 A MX 2013012991A MX 345331 B MX345331 B MX 345331B
Authority
MX
Mexico
Prior art keywords
saliva sample
joint disease
degenerative joint
diagnostic agent
amount
Prior art date
Application number
MX2013012991A
Other languages
English (en)
Other versions
MX2013012991A (es
Inventor
Scott Hannah Steven
Sherrill Scott
Li Qinghong
Sun Peichuan
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2013012991A publication Critical patent/MX2013012991A/es
Publication of MX345331B publication Critical patent/MX345331B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a métodos para diagnosticar enfermedad degenerativa de las articulaciones en un animal al tomar una muestra de saliva de un animal; determinar la cantidad de por lo menos un agente de diagnóstico seleccionado del grupo que consiste en interferón gamma, proteína-10 inducible o interferón, interleucina 2 y proteína de saliva total en la muestra de saliva; comparar (a cantidad de agente de diagnóstico encontrado en la muestra de saliva con una cantidad correspondiente del mismo agente de diagnóstico encontrado en una muestra de saliva de uno o más animales de control comparables que no sufran de enfermedad degenerativa de las articulaciones; y diagnosticar que el animal es susceptible a o sufre de enfermedad degenerativa de las articulaciones si la cantidad de agente de diagnóstico en la muestra de saliva del animal es mayor que la cantidad del mismo agente de diagnóstico encontrada en la muestra de saliva el uno o más animales de control comparables.
MX2013012991A 2011-05-10 2012-05-08 Métodos para diagnosticar enfermedad degenerativa de las articulaciones. MX345331B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161518707P 2011-05-10 2011-05-10
PCT/US2012/036863 WO2012154705A1 (en) 2011-05-10 2012-05-08 Methods for diagnosing degenerative joint disease

Publications (2)

Publication Number Publication Date
MX2013012991A MX2013012991A (es) 2013-12-06
MX345331B true MX345331B (es) 2017-01-25

Family

ID=47139583

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012991A MX345331B (es) 2011-05-10 2012-05-08 Métodos para diagnosticar enfermedad degenerativa de las articulaciones.

Country Status (12)

Country Link
US (1) US9322832B2 (es)
EP (1) EP2707717B1 (es)
JP (1) JP6018626B2 (es)
CN (1) CN103608679B (es)
AU (1) AU2012253691B2 (es)
BR (1) BR112013028678B1 (es)
CA (1) CA2835426C (es)
ES (1) ES2629829T3 (es)
MX (1) MX345331B (es)
RU (1) RU2603484C2 (es)
WO (1) WO2012154705A1 (es)
ZA (1) ZA201309259B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2706733C1 (ru) * 2019-08-06 2019-11-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ диагностики молекулярных фенотипов остеоартрита

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965379A (en) * 1991-07-19 1999-10-12 Cytimmune Sciences Inc. Method for measuring endogenous cytokines
US5756361A (en) * 1992-12-17 1998-05-26 Metra Biosystems, Inc. Screening method for periodontal disease
US5989294A (en) * 1998-07-29 1999-11-23 Marlow; Aaron L. Ball-and-socket joint, particularly a prosthetic hip joint
WO2006023412A2 (en) * 2004-08-18 2006-03-02 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Biomarkers for osteoarthritis
AU2006261641B2 (en) 2005-06-17 2011-09-29 The Brigham And Women's Hospital, Inc. Protein profile for osteoarthritis
EP2019619A4 (en) 2006-05-04 2010-07-21 Centocor Ortho Biotech Inc INFLAMMATORY DISEASE PROGRESSION, DIAGNOSTIC AND TREATMENT MONITORING PROCESSES, SYSTEMS, DEVICE AND USE
US20080199426A1 (en) * 2007-01-11 2008-08-21 Sukhatme Vikas P Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
US20080227747A1 (en) 2007-03-15 2008-09-18 Tabbiner Philip Composition and methods for treating or preventing degenerative joint and cardiovascular conditions
JP5663723B2 (ja) * 2008-05-14 2015-02-04 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 関節リウマチの診断のための方法およびキット
CA2792163A1 (en) * 2010-03-05 2011-09-09 The Curators Of The University Of Missouri Biomarkers of osteoarthritis
JP2013532128A (ja) 2010-05-12 2013-08-15 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 愛玩動物の炎症を抑制および予防し、炎症状態を緩和する方法

Also Published As

Publication number Publication date
JP6018626B2 (ja) 2016-11-02
EP2707717A1 (en) 2014-03-19
AU2012253691A1 (en) 2013-11-21
EP2707717B1 (en) 2017-05-03
CA2835426A1 (en) 2012-11-15
RU2013154556A (ru) 2015-06-20
US9322832B2 (en) 2016-04-26
EP2707717A4 (en) 2014-12-24
US20140147865A1 (en) 2014-05-29
BR112013028678A2 (pt) 2017-08-08
BR112013028678B1 (pt) 2021-07-13
CA2835426C (en) 2020-01-21
MX2013012991A (es) 2013-12-06
RU2603484C2 (ru) 2016-11-27
ES2629829T3 (es) 2017-08-16
JP2014514589A (ja) 2014-06-19
AU2012253691B2 (en) 2016-05-19
WO2012154705A1 (en) 2012-11-15
ZA201309259B (en) 2015-09-30
CN103608679B (zh) 2017-02-22
CN103608679A (zh) 2014-02-26

Similar Documents

Publication Publication Date Title
EP3770603A3 (en) Assay and method
CU24058B1 (es) Antagonistas de pcsk9
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
MX2013007067A (es) Anticuerpos anti-il-18 y sus usos.
MX2015012733A (es) Metodos y composiciones para evaluar el estado renal usando adn libre de celulas de la orina.
MX361731B (es) Método para diagnosticar cáncer y kit de diagnóstico usando medición de actividad de células nk.
MX2022013625A (es) Metodo para evaluar los efectos de una composicion que comprende microorganismos en la microbiota intestinal.
MX2016002719A (es) Proteina de union a interleucina 18 (il-18bp) en enfermedades inflamatorias.
MY195289A (en) Anti IL-36R Antibodies
EA201791186A1 (ru) Антитела к cd38
UA108912C2 (uk) БІЛОК, ЯКИЙ ЗВ'ЯЗУЄ TNF-α
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
TR201902439T4 (tr) Fukoz analogları kullanarak in vivo protein fukosilasyonunun inhibisyon yöntemleri .
WO2011088385A3 (en) Compositions and methods for detecting cancer
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
ECSP13012673A (es) Métodos y composiciones para inmunoterapia para enfermedad neural
IN2012DN06309A (es)
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
WO2015034886A3 (en) Wellness panel for companion animals
WO2012049225A3 (de) Markersequenzen für systemischer lupus erythematodes und deren verwendung
BR112013001229A2 (pt) peptídeo, método para o diagnóstico de uma doenaç autoimune, kit para o diagnóstico de uma doença autoimune, anticorpo direcionado contra o peptídeo
WO2013009146A3 (ko) 당뇨망막병증 진단용 마커 및 이의 용도
WO2014117680A3 (zh) 外周血细胞TRPC6mRNA水平用于早期预测/诊断老年性痴呆

Legal Events

Date Code Title Description
FG Grant or registration